No Data
No Data
Anhui Anke Biotechnology Plans to Invest 40 Million Yuan in Cell Therapy JV
Chinese Drug Regulator Accepts Anke Biotechnology's Supplementary Application for Eye Drops
Anhui Anke Biotechnology (300009.SZ): The supplemental registration application for the production of interferon α2b eye drops has been accepted.
Anhui Anke Biotechnology (300009.SZ) announced that the company has received the State Food and Drug Administration's administrative licensing document "Acceptance Letter."
Anhui Anke Biotechnology (Group) (SZSE:300009) Shareholders Have Endured a 36% Loss From Investing in the Stock Three Years Ago
Anke Biotech: 2024 Semi-Annual Report
Anke Biotech: 2024 Semi-Annual Report Summary
No Data
No Data